<DOC>
	<DOC>NCT00624780</DOC>
	<brief_summary>The purpose of this study is to characterize the safety and efficacy in patients with generalized anxiety disorder after short- (3 months) and long-term (6 months) use of Pregabalin (Lyrica).</brief_summary>
	<brief_title>Safety and Efficacy Evaluation Of Pregabalin (Lyrica) With Patients With Generalized Anxiety Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<mesh_term>Lorazepam</mesh_term>
	<criteria>Diagnosis Generalized Anxiety Disorder HAMA score &gt;=18 and HAMD (item 1) score &gt;=2 at screening and baseline Needs pharmacological treatment Current or past diagnosis of any other DSM IV Axis I disorders A history of failed treatment with a benzodiazepine Any clinically significant, serious, or unstable hematologic, autoimmune, endocrine, cardiovascular, renal, hepatic, gastrointestinal, or neurological disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>